Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$12.17 -3.4%	$11.67	$4.88 ▼ $19.58	$264.04M	N/A	96,323 shs	38,067 shs
FHTX Foghorn Therapeutics	$5.40	$4.50	$2.94 ▼ $10.25	$301.00M	3.05	142,637 shs	75,246 shs
INZY Inozyme Pharma	$4.00	$3.45	$0.72 ▼ $6.24	$258.25M	2.27	936,048 shs	N/A
KLTO Klotho Neurosciences	$1.30 -11.0%	$0.74	$0.11 ▼ $3.91	$42.24M	11.08	20.85 million shs	5.46 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-1.02%	-9.48%	+7.05%	+76.47%	+1,259,999,900.00%
FHTX Foghorn Therapeutics	-2.00%	+4.65%	+16.63%	+56.52%	+12.50%
INZY Inozyme Pharma	0.00%	0.00%	+0.50%	+351.42%	-13.42%
KLTO Klotho Neurosciences	+6.57%	+28.07%	-27.36%	+758.82%	+145,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	2.0324 of 5 stars	3.6	0.0	0.0	0.0	2.7	1.7	0.6
INZY Inozyme Pharma	3.4729 of 5 stars	4.2	4.0	0.0	0.0	2.0	2.5	0.0
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$33.00	171.16% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	124.54% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KLTO, FHTX, INZY, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	$22.60M	13.32	N/A	N/A	($0.82) per share	-6.59
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
KLTO Klotho Neurosciences	-$6.15M	-$0.36	N/A	∞	N/A	N/A	-1,779.01%	-275.01%	N/A

Latest KLTO, FHTX, INZY, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	KLTO Klotho Neurosciences	N/A	-$0.08	N/A	-$0.08	N/A	N/A
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	25.86	25.86
FHTX Foghorn Therapeutics	N/A	3.16	3.16
INZY Inozyme Pharma	0.65	2.19	2.19
KLTO Klotho Neurosciences	N/A	0.29	0.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
FHTX Foghorn Therapeutics	61.55%
INZY Inozyme Pharma	88.30%
KLTO Klotho Neurosciences	20.07%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
FHTX Foghorn Therapeutics	7.58%
INZY Inozyme Pharma	12.18%
KLTO Klotho Neurosciences	26.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
KLTO Klotho Neurosciences	N/A	32.49 million	23.82 million	N/A

KLTO, FHTX, INZY, and AARD Headlines

Recent News About These Companies

Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS

July 10 at 11:41 AM | ca.investing.com

Klotho Neurosciences Shares Jump as FDA Grants Orphan Drug Status for ALS Therapy

July 10 at 11:41 AM | msn.com

Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation

July 10 at 10:33 AM | proactiveinvestors.com

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

July 10 at 5:00 AM | prnewswire.com

Klotho Neurosciences (NASDAQ:KLTO) Rating Increased to Sell at Wall Street Zen

July 5, 2025 | americanbankingnews.com

KLTO - Klotho Neurosciences Inc Chart - Morningstar

July 2, 2025 | morningstar.comM

Klotho Neurosciences Begins Manufacturing Gene Therapy for ALS

July 2, 2025 | theglobeandmail.com

Klotho Neurosciences moves forward with manufacturing gene therapy to treat amyotrophic lateral sclerosis

July 1, 2025 | pharmabiz.comP

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

June 30, 2025 | prnewswire.com

Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population

June 24, 2025 | prnewswire.com

KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS

June 18, 2025 | prnewswire.com

KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

June 16, 2025 | prnewswire.com

Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?

June 10, 2025 | forbes.com

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon

June 10, 2025 | msn.com

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")

June 9, 2025 | prnewswire.com

Nasdaq Top 5 Premarket Losers: Healthcare Triangle, Klotho Neurosciences, New Fortress Energy, NanoVibronix, MDJM

May 15, 2025 | msn.com

Protein discovered that boosts lifespan, muscle, and brain power with just one dose

May 10, 2025 | earth.comE

Klotho: A protein that promotes healthy aging and improves longevity

May 9, 2025 | msn.com

Boosting Klotho Protein Slows Aging and Enhances Health

May 9, 2025 | neurosciencenews.comN

Klotho Neurosciences faces Nasdaq delisting risk

April 23, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLTO, FHTX, INZY, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$12.17 -0.43 (-3.41%)

As of 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Foghorn Therapeutics NASDAQ:FHTX

$5.40 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$5.39 -0.01 (-0.19%)

As of 05:23 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Klotho Neurosciences NASDAQ:KLTO

$1.30 -0.16 (-10.96%)

As of 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time